ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Adding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.
Docetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.
"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.
A recently published statement provides an evidence-based, consensus-driven framework on the role of genetic testing for determining prostate cancer risk, screening, and management.
The findings “[raise] the specter that patients could potentially receive different treatments depending on the cell-free DNA platform,” authors of a recent research letter write.
Among men undergoing active surveillance for low-risk prostate cancer, biennial biopsies appear to be an acceptable alternative to annual biopsies.
Patients with non-suspicious digital rectal exam findings and total PSA in the 4.0- to 10.0-ng/mL range are far less likely to be biopsied if they’ve undergone Prostate Health Index (phi) testing than if they don’t.
We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area.
Overexpression of a specific pair of genes might provide early warning of prostate cancer patients’ likelihood of progressing to metastatic disease.
There’s a troubling disconnect between low-risk prostate cancer patients’ desire to preserve sexual function and the treatment choices they and their doctors often make.